HomeCompareVTRU vs PFE

VTRU vs PFE: Dividend Comparison 2026

VTRU yields 22.05% · PFE yields 6.13%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 VTRU wins by $33.2K in total portfolio value
10 years
VTRU
VTRU
● Live price
22.05%
Share price
$9.07
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$82.7K
Annual income
$8,340.12
Full VTRU calculator →
PFE
Pfizer Inc.
● Live price
6.13%
Share price
$28.08
Annual div
$1.72
5Y div CAGR
13.2%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$49.6K
Annual income
$26,258.71
Full PFE calculator →

Portfolio growth — VTRU vs PFE

📍 VTRU pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodVTRUPFE
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, VTRU + PFE cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
VTRU pays
PFE pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

VTRU
Annual income on $10K today (after 15% tax)
$1,874.31/yr
After 10yr DRIP, annual income (after tax)
$7,089.10/yr
PFE
Annual income on $10K today (after 15% tax)
$520.66/yr
After 10yr DRIP, annual income (after tax)
$22,319.90/yr
At 15% tax rate, PFE beats the other by $15,230.80/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of VTRU + PFE for your $10,000?

VTRU: 50%PFE: 50%
100% PFE50/50100% VTRU
Portfolio after 10yr
$66.2K
Annual income
$17,299.42/yr
Blended yield
26.15%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on PFE right now

VTRU
Analyst Ratings
3
Buy
1
Hold
Consensus: Buy
Altman Z
0.9
Piotroski
6/9
PFE
Analyst Ratings
16
Buy
22
Hold
1
Sell
Consensus: Hold
Price Target
$27.50
-2.1% upside vs current
Range: $24.00 — $35.00
Altman Z
2.0
Piotroski
5/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

VTRU buys
0
PFE buys
8
PoliticianChamberTickerTypeAmountDate
Gilbert Cisneros🏢 House$PFE▲ Buy$1,001 - $15,0002026-02-10
Susan M. Collins🏛 Senate$PFE▲ Buy$15,001 - $50,0002026-02-03
James French Hill🏢 House$PFE▼ Sell$100,001 - $250,0002025-12-31
Gilbert Cisneros🏢 House$PFE▼ Sell$1,001 - $15,0002025-12-19
Ro Khanna🏢 House$PFE▼ Sell$1,001 - $15,0002025-09-15
Ro Khanna🏢 House$PFE▼ Sell$1,001 - $15,0002025-09-05
Gilbert Cisneros🏢 House$PFE▼ Sell$1,001 - $15,0002025-08-05
Lisa McClain🏢 House$PFE▲ Buy$1,001 - $15,0002025-07-16
Ron Wyden🏛 Senate$PFE▼ Sell$1,001 - $15,0002025-06-03
Ron Wyden🏛 Senate$PFE▼ Sell$1,001 - $15,0002025-06-03
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricVTRUPFE
Forward yield22.05%6.13%
Annual dividend / share$2.00$1.72
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%13.2%
Portfolio after 10y$82.7K$49.6K
Annual income after 10y$8,340.12$26,258.71
Total dividends collected$49.4K$58.3K
Payment frequencyquarterlyquarterly
SectorStockHealthcare
Analyst consensusBuyHold

Year-by-year: VTRU vs PFE ($10,000, DRIP)

YearVTRU PortfolioVTRU Income/yrPFE PortfolioPFE Income/yrGap
1← crossover$12,905$2,205.07$9,153$693.39+$3.8KVTRU
2$16,468$2,659.50$8,593$849.25+$7.9KVTRU
3$20,792$3,171.71$8,336$1,066.78+$12.5KVTRU
4$25,990$3,742.62$8,437$1,384.80+$17.6KVTRU
5$32,182$4,372.22$9,013$1,875.40+$23.2KVTRU
6$39,494$5,059.61$10,306$2,680.72+$29.2KVTRU
7$48,062$5,803.04$12,820$4,101.38+$35.2KVTRU
8$58,026$6,599.92$17,673$6,826.70+$40.4KVTRU
9$69,535$7,446.93$27,543$12,591.86+$42.0KVTRU
10$82,743$8,340.12$49,560$26,258.71+$33.2KVTRU

VTRU vs PFE: Complete Analysis 2026

VTRUStock

Vitru Limited, together with its subsidiaries, operates as a distance learning education company in the postsecondary digital education market in Brazil. It operates through three segments: Digital Education Undergraduate Courses, Continuing Education Courses, and On-Campus Undergraduate Courses. The company offers digital education undergraduate courses in hybrid methodology, which consists of weekly in-person meetings with on-site tutors. Its courses primarily comprise pedagogy, business administration, accounting, physical education, engineering, vocational education, and health-related courses. The company also offers continuing education courses primarily in pedagogy, finance, and business, as well as in other subjects, such as law, engineering, IT, and health-related courses through hybrid model, online, and on-campus. In addition, it operates 8 campuses that provides traditional on campus undergraduate courses, including business administration, accounting, physical education, engineering, law, and health-related courses. Vitru Limited was founded in 2014 and is headquartered in Florianópolis, Brazil.

Full VTRU Calculator →

PFEHealthcare

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and women's health under the Premarin family and Eliquis brands; biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Sutent, Inlyta, Retacrit, Lorbrena, and Braftovi brands; and sterile injectable and anti-infective medicines, and oral COVID-19 treatment under the Sulperazon, Medrol, Zavicefta, Zithromax, Vfend, Panzyga, and Paxlovid brands. The company also provides medicines and vaccines in various therapeutic areas, such as pneumococcal disease, meningococcal disease, tick-borne encephalitis, and COVID-19 under the Comirnaty/BNT162b2, Nimenrix, FSME/IMMUN-TicoVac, Trumenba, and the Prevnar family brands; biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Eucrisa/Staquis, and Cibinqo brands; and amyloidosis, hemophilia, and endocrine diseases under the Vyndaqel/Vyndamax, BeneFIX, and Genotropin brands. In addition, the company is involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, and individual provider offices, as well as disease control and prevention centers. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Myovant Sciences Ltd.; Akcea Therapeutics, Inc; Merck KGaA; Valneva SE; BioNTech SE; and Arvinas, Inc. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.

Full PFE Calculator →
📬

Get this VTRU vs PFE comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

VTRU vs SCHDVTRU vs JEPIVTRU vs OVTRU vs KOVTRU vs MAINVTRU vs JNJVTRU vs MRKVTRU vs ABBV

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.